---
figid: PMC7541692__nihms-1614039-f0001
figtitle: Dysregulation of the mitogen-activated protein kinase (MAPK) signaling pathway
  in melanoma
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC7541692
filename: nihms-1614039-f0001.jpg
figlink: /pmc/articles/PMC7541692/figure/F1/
number: F1
caption: Over 80% of melanomas possess genetic abnormalities in at least one key node
  in the MAPK signaling pathway. Oncogenic driver mutations in BRAF (V600E or V600K)
  are the most common genomic abnormalities observed in cutaneous melanoma, followed
  by mutations in NRAS, and the RAS GTPase activating protein (GAP), neurofibromin
  1 (NF1).
papertitle: Treatment of Advanced Melanoma in 2020 and Beyond.
reftext: Russell W. Jenkins, et al. J Invest Dermatol. ;141(1):23-31.
year: '2021'
doi: 10.1016/j.jid.2020.03.943
journal_title: The Journal of investigative dermatology
journal_nlm_ta: J Invest Dermatol
publisher_name: ''
keywords: ''
automl_pathway: 0.9232101
figid_alias: PMC7541692__F1
figtype: Figure
redirect_from: /figures/PMC7541692__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7541692__nihms-1614039-f0001.html
  '@type': Dataset
  description: Over 80% of melanomas possess genetic abnormalities in at least one
    key node in the MAPK signaling pathway. Oncogenic driver mutations in BRAF (V600E
    or V600K) are the most common genomic abnormalities observed in cutaneous melanoma,
    followed by mutations in NRAS, and the RAS GTPase activating protein (GAP), neurofibromin
    1 (NF1).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NF1
  - BRAF
  - NRAS
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - RAF1
---
